FDA ApprovedUnited States
New Weekly Shot for Protein Leak from IgA Kidney Disease
Trutakna (atacicept-vymj) — weekly under-the-skin shot to lower protein in the urine in adults with primary IgA nephropathy
FDA accelerated approval on 7 July 2026 for Trutakna (atacicept-vymj) injection — a weekly subcutaneous medicine — to reduce proteinuria in adults with primary…
This is for adults with primary IgA nephropathy who leak protein into the urine and may be candidates for labelled US Trutakna once-weekly home shots.